Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
TARTRATE SALT OF THIAZOLIDINEDIONE DERIVATIVE
This invention relates to a novel pharmaceutical, to a process for the
preparation
of the pharmaceutical and to the use of the pharmaceutical in medicine.
European Patent Application, Publication Number 0,306,228 relates to certain
thiazolidinedione derivatives disclosed as having hypoglycaemic and
hypolipidaemic
activity. The compound of example 30 of EP 0,306,228 is 5-[4-[2-(N-methyl-N-(2-
pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter also referred
to as
"Compound (I)").
International Patent Application, Publication Number W094/05659 discloses
certain salts of the compounds of EP 0,306,228 one of which is the tartrate
salt. The
preferred salt of W094/05659 is the malefic acid salt.
It has now been discovered that Compound (I) forms a novel tartrate salt
(hereinafter also referred to as the "DL-Tartrate"). Surprisingly, the
crystalline structure
of the DL-Tartrate is distinct from that of either the D-tartrate or the L-
tartrate salts or
solid mixtures of the D-and L-tartrate salts.
The novel DL-Tartrate is a stable, high melting crystalline material hence is
suitable for bulk preparation and handling. The DL- Taxtrate is amenable to
large scale
pharmaceutical processing, especially in manufacturing processes which require
or
generate heat, for example milling, fluid bed drying, spray drying, hot melt
processing
and sterilisation by autoclaving. The DL-Tartrate can also be prepared by an
efficient,
economic and reproducible process particularly suited to Large-scale
preparation.
The novel DL-tartrate also has useful pharmaceutical properties and in
particular
it is indicated to be useful for the treatment and/or prophylaxis of diabetes
mellitus,
conditions associated with diabetes mellitus and certain complications
thereof.
Accordingly, the present invention provides 5-[4-[2-(N-methyl-N-(2-
pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, DL-Tartrate salt or a
solvate
thereof.
Suitably, the DL-Tartrate is a mono-tartrate salt.
Mono tartrate salts also optionally comprise another monovalent salting ion
such
as an alkali metal or ammonium cation.
In one favoured aspect, the DL-Tartrate provides an infrared spectrum
substantially in accordance with Figure 1.
In one favoured aspect, the DL-Tartrate provides a Raman spectrum
substantially
in accordance with Figure 2.
In one favoured aspect, the DL-Tartrate provides an X-Ray powder diffraction
pattern (XRPD) substantially in accordance with Table 1 or Figure 3.
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
In one favoured aspect, the DL-tartrate provides a Solid State 13C NMR
spectrum
substantially in accordance with Figure 4.
In one favoured aspect, the DL- Tartrate provides a melting point in the range
of
from 190 to 195oC, such as 190 to 193 oC, fox example 191.7 oC
In a preferred aspect, the invention provides 5-[4-[2-(N-methyl-N-(2-
pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, DL-Tartrate salt,
characterised in
that it provides:
(i) an infrared spectrum substantially in accordance with Figure l; and
(ii) a Raman spectrum substantially in accordance with Figure 2;and
(iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance
with Table
1 or Figure 3 ;and
(iv) a Solid State 1'C NMR spectrum substantially in accordance with Figure 4.
The present invention encompasses the DL-Tartrate or solvate thereof isolated
in
pure form or when admixed with other materials. Thus in one aspect there is
provided
the DL-Tartrate or solvate thereof in isolated form.
In a further aspect there is provided the DL-Tartrate or solvate thereof in a
purified form.
In yet a further aspect there is provided the DL-Tartrate or solvate thereof
in
crystalline form.
Also, the invention provides the DL-Tartrate or solvate thereof in a solid
pharmaceutically acceptable form, such as a solid dosage form, especially when
adapted
for oral administration.
Moreover, the invention also provides the DL-Tartrate or solvate thereof in a
pharmaceutically acceptable form, especially in bulls form, such form being
particularly
capable of pharmaceutical processing, especially in manufacturing processes
which
require or generate heat, for example milling; for example heat-drying
especially fluid-
bed drying or a spray drying; for example hot melt processing; for example
heat-
sterilisation such as autoclaving.
Furthermore, the invention provides the DL-Tartrate or solvate thereof in a
pharmaceutically acceptable form, especially in bulk form.and especially in
form having
been processed in a manufacturing process requiring or generating heat, for
example in
a milled form; for example in heat-dried form, especially a fluid-bed dried
form or a
spray dried form; for example in a form having being hot melt processed; for
example in
a form having being heat-sterilised by such as autoclaving.
A suitable solvate is a hydrate.
The invention also provides a process for preparing the DL-Tartrate or a
solvate
thereof, characterised in that 5-[4-[2-(N-methyl-N-(2-
2
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)) or a salt
thereof,
preferably dispersed or dissolved in a suitable solvent, is reacted with a
source of DL
tartrate ion and thereafter, if required, a solvate of the resulting DL-
Tartrate is prepared;
and the DL-Tartrate or a solvate thereof is recovered.
A suitable reaction solvent is an alkanol, for example propan-2-ol, or a
hydrocarbon, such as toluene, a ketone, such as acetone, an ester, such as
ethyl acetate, an
ether such as tetrahydrofuran, a nitrile such as acetonitrile, or a
halogenated hydrocarbon
such as dichloromethane or water, or an organic acid such as acetic acid; or a
mixture
thereof.
Conveniently, the source of DL-tartrate ion is DL-tartaric acid. The DL-
tartaric
acid is preferably added as a solid or in solution, for example in water or a
lower alcohol
such as methanol, ethanol, or propan-2-ol, or a mixture of solvents. An
alternative source
of DL-tartrate ion is provided by a suitably soluble base salt of tartaric
acid for example
ammonium tartrate, or the tartaric acid salt of an amine, for example
ethylamine or
diethylamine.
The concentration of Compound (I) is preferably in the range 2 to 25%
weight/volume, more preferably in the range 5 to 20%. The concentration of
tartaric acid
solutions are preferably in the range range of 4 to 40% weightlvolume.
The reaction is usually carried out at ambient temperature or at an elevated
temperature, for example at the reflux temperature of the solvent, although
any
convenient temperature that provides the required product may be employed.
Solvates, such as hydrates, of the DL-Tartrate are prepared according to
conventional procedures.
Recovery of the required compound generally comprises crystallisation from an
appropriate solvent or mixture of solvents, conveniently the reaction solvent,
usually
assisted by cooling. For example, the DL- tartrate may be crystallised from an
alcohol
such as ethanol or a ketone such as acetone or water or a mixture thereof. An
improved
yield of the salt may be obtained by evaporation of some or all of the solvent
or by
crystallisation at elevated temperature followed by controlled cooling,
optionally in
stages. Careful control of precipitation temperature may be used to improve
the
reproducability product form.
Crystallisation can also be initiated by seeding with crystals of the DL-
Tartrate or
a solvate thereof but this is not essential.
When the mono tartrate salt comprise another monovalent salting ion such as an
alkali metal or ammonium cation.the said ion is conveniently formed by
reacting the
mono tartrate salt with a solution of the chosen monovalent salting ion for
example a
3
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
metal or ammonium ion. Alternatively Compound(I) may be treated with a mono
tartrate
salt of the said monovalent salting ion.
Compound (I) is prepared according to known procedures, such as those
disclosed
in EP 0,306,228 and WO94/05659. The disclosures of EP 0,306,228 and W094/05659
are incorporated herein by reference.
DL tartaric acid is a commercially available compound.
When used herein the term "Tonset" is generally determined by Differential
Scanning Calorimetry and has a meaning generally understood in the art, as for
example expressed in Pharmaceutical Thermal Analysis, Techniques and
Applications", Ford and Timmins, 1989 as "The temperature corresponding to the
intersection of the pre-transition baseline with the extrapolated leading edge
of the
transition" .
When used herein the term'prophylaxis of conditions associated with diabetes
mellitus' includes the treatment of conditions such as insulin resistance,
impaired glucose
tolerance, hyperinsulinaemia and gestational diabetes.
Diabetes mellitus preferably means Type II diabetes mellitus.
Conditions associated with diabetes include hyperglycaemia and insulin
resistance
and obesity. Further conditions associated with diabetes include hypertension,
cardiovascular disease, especially atherosclerosis, certain eating disorders,
in particular
the regulation of appetite and food intake in subjects suffering from
disorders associated
with under-eating, such as anorexia nervosa, and disorders associated with
over-eating,
such as obesity and anorexia bulimia. Additional conditions associated with
diabetes
include polycystic ovarian syndrome and steroid induced insulin resistance.
The complications of conditions associated with diabetes mellitus encompassed
herein includes renal disease, especially renal disease associated with the
development of
Type II diabetes including diabetic nephropathy, glomerulonephritis,
glomerular
sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage
renal disease.
As mentioned above the compound of the invention has useful therapeutic
properties: The present invention accordingly provides the DL-Tartxate or a
solvate
thereof for use as an active therapeutic substance.
More particularly, the present invention provides the DL-Tartrate or a solvate
thereof for use in the treatment andlor prophyla<Yis of diabetes mellitus,
conditions
associated with diabetes mellitus and certain complications thereof.
The DL-Tartrate or a solvate thereof may be administered per se or,
preferably, as
a pharmaceutical composition also comprising a pharmaceutically acceptable
carrier.
Suitable methods for formulating the DL-Tartrate or a solvate thereof are
generally those
disclosed for Compound (I) in the above mentioned publications.
4
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
Accordingly, the present invention also provides a pharmaceutical composition
comprising the DL-Tartrate or a solvate thereof and a pharmaceutically
acceptable carrier
therefor.
The DL-Tartrate or a solvate thereof is normally administered in unit dosage
form.
The active compound may be administered by any suitable route but usually by
the oral or parenteral routes. For such use, the compound will normally be
employed in
the form of a pharmaceutical composition in association with a pharmaceutical
carrier,
diluent and/or excipient, although the exact form of the composition will
naturally depend
on the mode of administration.
Compositions are prepared by admixture and are suitably adapted for oral,
parenteral or topical administration, and as such may be in the form of
tablets, capsules,
oral liquid preparations, powders, granules, lozenges, pastilles,
reconstitutable powders,
injectable and infusable solutions or suspensions, suppositories and
transdermal devices.
Orally administrable compositions are preferred, in particular shaped oral
compositions,
since they are more convenient for general use.
Tablets and capsules for oral administration are usually presented in a unit
dose,
and contain conventional excipients such as binding agents, fillers, diluents,
tabletting
agents, lubricants, disintegrants, colourants, flavourings, and wetting
agents. The tablets
may be coated according to well known methods in the art.
Suitable fillers for use include cellulose, mannitol, lactose and other
similar
agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch
derivatives
such as sodium starch glycollate. Suitable lubricants include, for example,
magnesium
stearate. Suitable pharmaceutically acceptable wetting agents include sodium
lauryl
sulphate.
Solid oral compositions may be prepared by conventional methods of blending,
filling, tabletting or the like. Repeated blending operations may be used to
distribute the
active agent throughout those compositions employing large quantities of
fillers. Such
operations are, of course, conventional in the art.
Oral liquid preparations may be in the form of, for example, aqueous or oily
suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as
a dry product
for reconstitution with water or other suitable vehicle before use. Such
liquid
preparations may contain conventional additives such as suspending agents, for
example
sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose,
carboxymethyl cellulose,
aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for
example
lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may
include edible
oils), for example, almond oil, fractionated coconut oil, oily esters such as
esters of
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
glycerine, propylene glycol, or ethyl alcohol; preservatives, for example
methyl or propyl
p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or
colouring
agents.
For parenteral administration, fluid unit dose forms are prepared containing a
compound of the present invention and a sterile vehicle. The compound,
depending on
the vehicle and the concentration, can be either suspended or dissolved.
Parenteral
solutions are normally prepared by dissolving the active compound in a vehicle
and filter
sterilising before f fling into a suitable vial or ampoule and sealing.
Advantageously,
adjuvants such as a local anaesthetic, preservatives and buffering agents are
also
dissolved in the vehicle. To enhance the stability, the composition can be
frozen after
filling into the vial and the water removed under vacuum.
Parenteral suspensions are prepared in substantially the same manner except
that
the active compound is suspended in the vehicle instead of being dissolved and
sterilised
by exposure to ethylene oxide before suspending in the sterile vehicle.
Advantageously,
a surfactant or wetting agent is included in the composition to facilitate
uniform
distribution of the active compound.
As is common practice, the compositions will usually be accompanied by written
or printed directions fox use in the medical treatment concerned.
As used herein the term 'pharmaceutically acceptable' embraces compounds,
compositions and ingredients for both human and veterinary use: for example
the term
'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
The present invention further provides a method for the treatment and/or
prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus
and certain
complications thereof, in a human or non-human mammal which comprises
administering
an effective, non-toxic, amount of DL-Tartrate or a solvate thereof to a human
or
non-human mammal in need thereof.
Conveniently, the active ingredient may be administered as a pharmaceutical
composition hereinbefore defined, and this forms a particular aspect of the
present
invention.
In a further aspect the present invention provides the use of DL-Tartrate or a
solvate thereof for the manufacture of a medicament for the treatment and/or
prophylaxis
of diabetes mellitus, conditions associated with diabetes mellitus and certain
complications thereof.
In the treatment and/or prophylaxis of diabetes mellitus, conditions
associated
with diabetes mellitus and certain complications thereof the DL-Tartrate or a
solvate
thereof may be taken in amounts so as to provide Compound (I) in suitable
doses, such as
those disclosed in EP 0,306,228, W094/05659 or W098/55122.
6
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
No adverse toxicological effects are indicated in the above mentioned
treatments
for the compounds of the invention.
The following examples illustrate the invention but do not limit it in any
way.
7
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
EXAMPLES
Example 1 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-B,4-
dione
DL tartrate
A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-
2,4-
dione (10 g) and ethanol (300 ml) was stirred and heated to reflux to give a
clear solution. A
hot solution of DL-tartaric acid (4.2 g) in ethanol (80 ml) (prepared by
heating to reflux for
15 minutes) was added. The solution was stirred at reflux until
crystallisation was observed
and the mixture was then cooled to 21 °C and stirred at this
temperature for 2.5 hours. The
product was collected by filtration, washed with ethanol (100 ml) and dried
under vacuum
over phosphorus pentoxide for 4 hours to provide 5-[4-[2-(N-methyl-N-(2-
pyridyl)amino)ethoxy] benzyl]thiazolidine-2,4-dione DL-tartrate (14.2 g) as a
white
crystalline solid.
1H-NMR (d6-DMSO): consistent with 5-[4-[2-(N-methyl-N-(2-
pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione DL-tartrate.
Example 2 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-
dione DL-Tartrate
A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]
thiazolidine-2,4-dione (3.0 g) and acetone (50 ml) was heated at reflux with
stirnng for
50 minutes. To this was added a hot clear solution of DL-tartaric acid (1.27
g) in water
(6.0 ml). The reaction mixture was heated at reflux for 5 minutes, then cooled
to 21°C.
The white solid was collected by filtration, washed with acetone (50 ml) then
dried under
reduced pressure for 1.8 hours at 21 °C to afford 5-[4-[2-(N-methyl-N-
(2-
pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione DL-tartrate (4.0 g) as a
white
crystalline solid.
Characterising data recorded for the product of Example 1
The infrared absorption spectrum of a mineral oil dispersion of the product
was
obtained using a Nicolet 710 FT-IR spectrometer at 2 cm-1 resolution (Figure
1). Data
were digitised at 1 cm-1 intervals. Bands were observed at: 3451, 1751, 1696,
1639,
1630, 1610, 1539, 1513, 1461, 1414, 1378, 1352, 1287, 1269, 1234, 1208, 1175,
1155, 1133, 1076, 1058, 1000, 922, 902, 839, 750, 713, 673, 600, 525, 508 cm-
1.
The infrared spectrum of the solid product was recorded using Perkin-Elmer
Spectrum One FT-IR spectrometer fitted with a universal ATR accessory. Bands
were
observed at: 3457, 3070, 2785, 1750, 1694, 1639, 1628, 1610, 1543, 1512, 1462,
1414, 1352, 1314, 1287, 1270, 1233, 1208, 1185, 1175, 1153, 1132, 1075, 1057,
1039, 1001, 983, 922, 902, 838, 827, 775, 749, 712, 668 cm-1.
8
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
The Raman spectrum of the product (Figure 2) was recorded with the sample in
an NMR tube using a Nicolet 960 E.S.P. FT-Raman spectrometer, at 4 cm-1
resolution
with excitation from a Nd:V04 laser (1064 nm) with a power output of 400mW.
Bands
were observed at: 3103, 3046, 2956, 2924, 2901, 2859, 1749, 1712, 1610, 1584,
1545,
1463, 1444, 1384, 1353, 1333, 1316, 1292, 1240, 1208 1185, 1174, 1152, 1112,
1095,
1039, 984, 922, 902, 828, 778, 742, 667, 637, 622, 601, 540, 471, 422, 401,
347,
282, 108 cm-1.
The X-Ray Powder Diffractogram pattern of the product (Figure 3) was recorded
using
the following acduisition conditions: Tube anode: Cu, Generator tension: 40
kV, Generator
current: 40 mA, Start angle: 2.0 °28, End angle: 35.0 °20, Step
size: 0.02 °20 , Time per step:
2.5 seconds.Characteristic XRPD angles and relative intensities are recorded
in Table 1.
Table 1
Angle Rel.lntensity
2-Theta
6.4 15.3
8.3 1.7
10.4 3.2
12.4 5
12.7 4.9
13.4 27.8
14.0 18.9
14.4 8.3
15.2 8.5
16.1 10.1
16.6 13.2
17.1 23.6
17.8 100
18.4 10
18.6 24.3
19.6 5
20.0 28.8
20.3 12.3
20.9 22.7
21.8 26.2
22.1 41.8
22.9 17.2
23.5 14.3
23.8 34.4
9
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
24.0 22.3
24.4 15.4
24.9 39.6
25.6 14.5
25.9 16.8
26.7 24.5
26.9 26.3
27.7 12.2
27.9 10.6
28.8 33.8
29.1 12.7
30.0 11.9
30.6 17.4
31.5 9.3
32.0 7.3
32.5 6.1
33.4 7.4
34.2 8.7
34.6
The solid-state NMR spectrum of the product (Figure 4) was recorded on a
Broker AMX360
instrument operating at 90.55 MHz: The solid was packed into a 4 mm zirconia
MAS rotor
fitted with a Kel-F cap and rotor spun at ca.l0 kHz. The 13C MAS spectrum was
acquired
by cross-polarisation from Hartmann-Hahn matched protons (CP contact time 3ms,
repetition
time 1S s) and protons were decoupled during acquisition using a two-pulse
phase modulated
(TPPM) composite sequence. Chemical shifts were externally referenced to the
carboxylate
signal of glycine at 176.4 ppm relative to TMS and were observed at:
177.9, 176.7, 174.6, 169.9, 156.3, 147.9, 137.5, 132.5, 126.3, 117.1, 116.1,
112.6, 111.1,
109.8, 107.2, 74.2, 72.3, 65.9, 55.7, 49.5, 40.2, 38.3, 35.1 ppm.
Properties of the DL-Tartrate, recorded for the product of Example 1
Solid State Stability of the DL-Tartrate
The solid state stability of the drug substance was determined by storing
approximately
1.0 g of the material in a glass bottle at i) 40°C / 75 % Relative
Humidity (RH), open
exposure, for 1 month and b) at SOoC, closed, for 1 month. The material was
assayed
by HPLC for final content and degradation products in both cases.
a) 40oC / 75 % RH: No significant degradation observed (HPLC assay 97 %
initial).
b) 50oC: No significant degradation observed (HPLC assay 99% initial).
I0
CA 02417827 2003-02-03
WO 02/12232 PCT/GBO1/03511
Melting Point of the DL-Tartrate
The melting point of the DL-Tartrate was determined according to the method
described in
the U.S. Pharmacopoeia, USP 23, 1995, <741 > "Melting range or temperature,
Procedure
for Class Ia", using a Buchi 545 melting point instrument.
Melting Point: 191.7oC
Tonset of the DL-Tartrate
The To~et of the drug substance was determined by Differential Scanning
Calorimetry
using a Perkin-Elmer DSC7 apparatus.
Tonset ~lOoC/minute, closed pan): 202 °C
Solubility of the DL-Tartrate
The solubility of the material was determined by adding water in aliquots from
1 to
1000m1 to approximately 100mg of drug substance until the powder had
dissolved. The
visual solubility was confirmed by an HPLC assay of a saturated solution.
Solubility: 1mg/ml.
11
